

NATIONAL QUALITY FORUM

Cardiovascular Project 2015

VOTING BALLOT

MEASURE-BY-MEASURE

0067

Chronic Stable Coronary Artery Disease: Antiplatelet Therapy

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

0068

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

0070

Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

0071

Persistence of Beta-Blocker Treatment After a Heart Attack

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

0079

Heart Failure: Left Ventricular Ejection Fraction Assessment (Outpatient Setting)

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

0081

Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

eMeasure 0081 _____ _____ _____	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) I approve the measure currently specified I disapprove the measure currently specified I abstain from voting on this measure
0083 _____ _____ _____	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) I approve the measure currently specified I disapprove the measure currently specified I abstain from voting on this measure
eMeasure 0083 _____ _____ _____	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) I approve the measure currently specified I disapprove the measure currently specified I abstain from voting on this measure
0229 _____ _____ _____	Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following heart failure (HF) hospitalization for patients 18 and older I approve the measure currently specified I disapprove the measure currently specified I abstain from voting on this measure
0230 _____ _____ _____	Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following acute myocardial infarction (AMI) hospitalization for patients 18 and older I approve the measure currently specified I disapprove the measure currently specified I abstain from voting on this measure
0669 _____ _____ _____	Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac, Low Risk Surgery I approve the measure currently specified I disapprove the measure currently specified I abstain from voting on this measure
0694 _____ _____ _____	Hospital Risk-Standardized Complication Rate following Implantation of Implantable Cardioverter-Defibrillator (ICD) I approve the measure currently specified I disapprove the measure currently specified I abstain from voting on this measure

0730

Acute Myocardial Infarction (AMI) Mortality Rate

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

0965

Discharge Medications (ACE/ARB and beta blockers) in Eligible ICD Implant Patients

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

2396

Carotid artery stenting: Evaluation of Vital Status and NIH Stroke Scale at Follow Up

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

2712

Statin Use in Persons with Diabetes

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure

2764

Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy

I approve the measure currently specified

I disapprove the measure currently specified

I abstain from voting on this measure